The administration has begun to incorporate harm-reduction language in its approach to drug control, which represents a major shift in U.S. policy.
User fees have historically been used to bolster the FDA’s work in reviewing the safety and efficacy of drugs, and must be renewed every five years.
More than two years into the pandemic, the long-needed data modernization push remains dormant.
Tuesday afternoon’s webinar made it clear just how challenging it will be for the Biden administration to effect meaningful policy reform.
As Democrats seek to revive Build Back Better, drug pricing reform tops the list of provisions likely to make the final cut.
A push to deliver home tests and high-quality masks is set to replace the previous emphasis on vaccination.
Some experts argue that the current Build Back Better pricing scheme will hinder cancer research and care.
The CDC has tweaked its messaging to focus on harm reduction. It hasn’t made any difference.
Why public health experts believe communications around Omicron need to toe the line between too much concern and just enough.
The Biden administration’s initiative to boost manufacturing capacity launches with great ambitions and expectations.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to: